Клиническая эффективность серетида у больных ХОБЛ. По материалам исследования TRISTAN

1. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids Am. J. Respir. Crit. Care Med. 1998; 157: s51-s53.

2. Barnes P.J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Ibid. 1999; 160 (5): S72-S79.

3. Cazzola М., Lorenzo G.D., Perna F.D. et al. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000; 118: 1576-1581.

4. Global initiative for chronic obstructive lung disease. National Heart, Lung, and Blood Institute, NIH and World Health Organization. Executive summary. Bethesda; 2000.

5. NHLBI/WHO Workshop report: Global strategy for asthma management and prevention. NIH publication № 02-3659. Bethesda; 2002. 1-177.

6. Postma D.S., Kerstjens H.A.M. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 1999; 160: S66-S71.

7. Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 2000; 320: 1368-1379.

8. TRISTAN COPD study. TRISTAN COPD Newsletter 09.10.2001; 1-21.